Business
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that new preclinical data demonstrating enhanced tumor control of the combination of an INTASYL compound targeting CTLA-4 and a systemic anti-PD-1 antibody will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in San Diego, California from November 1-5, 2023. Presentation Details are as follows: Title: Intratumoral CTLA-4-targeting INTASYL™ self-delivering RNAi enhances tumor control in combination with systemic anti-PD-1 antibody therapy in vivo suggesting a strategy to mitigate irSAEsAbstract #: 474Presenting Author: Melissa MaxwellDate and Time: 9:00 am - 8:30 pm PST on Saturday, November 4, 2023Location: Exhibit Halls A and B1 – San Diego Convention Center The poster presentation will be accessible in person and will also be made available on the \"Investors – Events and Presentations\" section of the Company's website (click here). About Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. For additional information, visit the Company’s website, www.phiopharma.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as \"intends,\" \"believes,\" \"anticipates,\" \"indicates,\" \"plans,\" \"expects,\" \"suggests,\" \"may,\" \"would,\" \"should,\" \"potential,\" \"designed to,\" \"will,\" \"ongoing,\" \"estimate,\" \"forecast,\" \"target,\" \"predict,\" \"could\" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, e...